{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:45Z","timestamp":1758050325559,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bulcan.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T07:51:19Z","timestamp":1681458679000},"page":"855-864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sarcomes ut\u00e9rins du stroma de haut grade et sarcomes indiff\u00e9renci\u00e9s\u00a0\u2013\u00a0R\u00e9f\u00e9rentiels de prise en charge du Groupe Sarcome Fran\u00e7ais et du Groupe des Tumeurs Rares Gyn\u00e9cologiques"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-3844","authenticated-orcid":false,"given":"Cyril","family":"Roussel-Simonin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Llacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Genestie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Malhaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.03.017_bib0270","article-title":"WHO classification of tumours of female reproductive organs","volume":"24","author":"Tavassoli","year":"2020"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.017_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e31824a7b1a","article-title":"The clinicopathologic features of YWHAE-FAM22\u00a0endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor","volume":"36","author":"Lee","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.017_bib0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.017_bib0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijgo.2013.01.025","article-title":"Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy","volume":"122","author":"Malouf","year":"2013","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.017_bib0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.05.036","article-title":"Low-grade and high-grade endometrial stromal sarcoma: a national cancer database study","volume":"146","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.03.017_bib0165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1073\/pnas.1115528109","article-title":"14-3-3\u00a0fusion oncogenes in high-grade endometrial stromal sarcoma","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.017_bib0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAS.0000000000000721","article-title":"Novel high-grade endometrial stromal sarcoma: a morphologic mimicker of myxoid leiomyosarcoma","volume":"41","author":"Hoang","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.017_bib0175","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/PAS.0000000000000697","article-title":"BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities","volume":"40","author":"Kao","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.03.017_bib0180","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/PAS.0b013e31825fa931","article-title":"Cyclin D1\u00a0as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22\u00a0rearrangement","volume":"36","author":"Lee","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.bulcan.2023.03.017_bib0185","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/PAS.0b013e31816a3b42","article-title":"Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31\u00a0cases","volume":"32","author":"Kurihara","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.017_bib0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PAS.0000000000001375","article-title":"SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct clinicopathologic entities","volume":"44","author":"Kolin","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.03.017_bib0195","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41379-019-0303-z","article-title":"SMARCA4\u00a0inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association","volume":"32","author":"Lin","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2023.03.017_bib0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijgo.12613","article-title":"Uterine sarcomas","volume":"143","author":"Mbatani","year":"2018","journal-title":"Int J Gynecol Obstet"},{"issue":"00","key":"10.1016\/j.bulcan.2023.03.017_bib0205","first-page":"7","article-title":"Validation of a mitotic index cutoff as a prognostic marker in undifferentiated uterine sarcomas","volume":"00","author":"Hardell","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.017_bib0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2012.06.030","article-title":"High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes","volume":"127","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.017_bib0215","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ijc.29141","article-title":"A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22\u00a0translocation status as predictors of survival","volume":"136","author":"Gremel","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.017_bib0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/ijgc-2018-000064","article-title":"Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group","volume":"29","author":"Meurer","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.017_bib0225","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.017_bib0230","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.017_bib0235","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3\u00a0trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.03.017_bib0240","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3\u00a0trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"year":"2021","author":"European Organisation for Research and Treatment of Cancer\u00a0\u2013\u00a0EORTC","key":"10.1016\/j.bulcan.2023.03.017_bib0245"},{"key":"10.1016\/j.bulcan.2023.03.017_bib0250","doi-asserted-by":"crossref","first-page":"v707","DOI":"10.1093\/annonc\/mdz283.064","article-title":"EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)","volume":"30","author":"Penel","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2023.03.017_bib0255","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2023.03.017_bib0260","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.03.017_bib0265","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/cncr.11730","article-title":"A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma","volume":"98","author":"Talbot","year":"2003","journal-title":"Cancer"},{"issue":"9829","key":"10.1016\/j.bulcan.2023.03.017_bib0135","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"379","author":"Graaf","year":"2012","journal-title":"Lancet"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:12Z","timestamp":1757792232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":27,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0007455123001613"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcomes ut\u00e9rins du stroma de haut grade et sarcomes indiff\u00e9renci\u00e9s\u00a0\u2013\u00a0R\u00e9f\u00e9rentiels de prise en charge du Groupe Sarcome Fran\u00e7ais et du Groupe des Tumeurs Rares Gyn\u00e9cologiques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}